122 related articles for article (PubMed ID: 22228348)
41. Incidental detection of gastrointestinal stromal tumor by Tc-99m MDP bone scan.
Shepherd TM; Idakoji IA; Pampaloni MH
Clin Nucl Med; 2012 Feb; 37(2):198-9. PubMed ID: 22228353
[TBL] [Abstract][Full Text] [Related]
42. The characteristics of FDG PET/CT imaging in pulmonary Langerhans cell sarcoma.
Chen YW; Chang CC; Hou PN; Yin SL; Lai YC; Hou MF
Clin Nucl Med; 2012 May; 37(5):495-7. PubMed ID: 22475903
[TBL] [Abstract][Full Text] [Related]
43. Giant pulmonary chondroid hamartoma: imaging and pathology correlation of a rare tumor demonstrated with bone scintigraphy and 18F-FDG PET/CT.
Lio E; Aisner DL; Askin FB; Kwak JJ
Clin Nucl Med; 2015 Jan; 40(1):79-81. PubMed ID: 25275419
[TBL] [Abstract][Full Text] [Related]
44. SPECT-CT for characterization of extraosseous uptake of 99mTc-methylene diphosphonate on bone scintigraphy.
Soundararajan R; Naswa N; Sharma P; Karunanithi S; Nazar AH; Das KJ; Bal C; Malhotra A; Kumar R
Diagn Interv Radiol; 2013; 19(5):405-10. PubMed ID: 23748034
[TBL] [Abstract][Full Text] [Related]
45. Differential washout of FDG activity in two different inflammatory lesions: implications for delayed imaging.
Cheng G; Alavi A; Del Bello CV; Akers SR
Clin Nucl Med; 2013 Jul; 38(7):576-9. PubMed ID: 23640221
[TBL] [Abstract][Full Text] [Related]
46. Crowned dens syndrome diagnosed on ¹⁸F-FDG PET/CT.
Monet A; Massonnat R; Merino B; Riviere A; Richez C
Clin Nucl Med; 2014 Dec; 39(12):1041-2. PubMed ID: 25243939
[TBL] [Abstract][Full Text] [Related]
47. Missed causative tumors in diagnosing tumor-induced osteomalacia with (18)F-FDG PET/CT: a potential pitfall of standard-field imaging.
Kaneuchi Y; Hakozaki M; Yamada H; Hasegawa O; Tajino T; Konno S
Hell J Nucl Med; 2016; 19(1):46-8. PubMed ID: 26929940
[TBL] [Abstract][Full Text] [Related]
48. Hypertrophic pulmonary osteoarthropathy diagnosed by FDG PET-CT in a patient with lung adenocarcinoma.
Makis W; Abikhzer G; Rush C
Clin Nucl Med; 2009 Sep; 34(9):625-7. PubMed ID: 19692831
[TBL] [Abstract][Full Text] [Related]
49. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?
Ulaner GA; Magnan H; Healey JH; Weber WA; Meyers PA
AJR Am J Roentgenol; 2014 Apr; 202(4):859-67. PubMed ID: 24660717
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography/computed tomography imaging.
Pires AO; Borges US; Lopes-Costa PV; Gebrim LH; da Silva BB
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():138-41. PubMed ID: 25037283
[TBL] [Abstract][Full Text] [Related]
51. Primary Rosai-Dorfman disease of the bone in a patient with history of breast cancer: appearance on 99mTc-MDP scintigraphy, CT, and X-ray.
Mannelli L; Monti S; Love JE; Kussick SJ; McLuen A; Behnia F
Clin Nucl Med; 2015 Mar; 40(3):247-9. PubMed ID: 25290290
[TBL] [Abstract][Full Text] [Related]
52. A report on the incidence of intestinal 99mTc-methylene diphosphonate uptake of bone scans and a review of the literature.
Ergün EL; Kiratli PO; Günay EC; Erbaş B
Nucl Med Commun; 2006 Nov; 27(11):877-85. PubMed ID: 17021428
[TBL] [Abstract][Full Text] [Related]
53. Tc-99m MDP bone scintigraphy and positron emission tomography/computed tomography (PET/CT) imaging in Erdheim-Chester disease.
Namwongprom S; Núñez R; Kim EE; Macapinlac HA
Clin Nucl Med; 2007 Jan; 32(1):35-8. PubMed ID: 17179801
[No Abstract] [Full Text] [Related]
54. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
55. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
56. CT, MRI, and FDG PET/CT in a patient with alveolar soft part sarcoma.
Dong A; Wang Y; Cheng C; Zuo C
Clin Nucl Med; 2014 Mar; 39(3):265-7. PubMed ID: 23856828
[TBL] [Abstract][Full Text] [Related]
57. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
[TBL] [Abstract][Full Text] [Related]
58. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
59. FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy.
Schmidt GP; Paprottka P; Jakobs TF; Hoffmann RT; Baur-Melnyk A; Haug A; Notohamiprodjo M; Baur-Melnyk A; Nikolaou K; Reiser MF; Rist C
Eur J Radiol; 2012 Mar; 81(3):e269-76. PubMed ID: 21398060
[TBL] [Abstract][Full Text] [Related]
60. 99mTc-MDP- and 18F-FDG-avid metastatic liver lesion: the similarities and differences between 2 modalities.
Aras M; Dede F; Ones T; Dane F; Inanir S; Erdil TY; Turoglu HT
Clin Nucl Med; 2012 Apr; 37(4):380-1. PubMed ID: 22391711
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
